Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Franziska SchudererChair of Medicinal and Bioinorganic Chemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich Lichtenbergstrasse 4 85748 Garching bei München Germany angela.casini@tum.de.ORCID https://orcid.org/0009-0006-3447-8549
Rúben D M SilvaCentro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, CTN, LRS Estrada Nacional 10 2695-066 Bobadela Portugal jgalamba@ctn.tecnico.ulisboa.pt fmendes@ctn.tecnico.ulisboa.pt.ORCID https://orcid.org/0000-0003-3665-9571
Catarina I G PintoCentro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, CTN, LRS Estrada Nacional 10 2695-066 Bobadela Portugal jgalamba@ctn.tecnico.ulisboa.pt fmendes@ctn.tecnico.ulisboa.pt.ORCID https://orcid.org/0000-0002-4195-5810
Lena KollerDepartment of Nuclear Medicine, TUM University Hospital, Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, Technical University of Munich 81675 Munich Germany s.kossatz@tum.de.
Stefan StanglDepartment of Nuclear Medicine, TUM University Hospital, Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, Technical University of Munich 81675 Munich Germany s.kossatz@tum.de.
Lurdes GanoCentro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, CTN, LRS Estrada Nacional 10 2695-066 Bobadela Portugal jgalamba@ctn.tecnico.ulisboa.pt fmendes@ctn.tecnico.ulisboa.pt.
Miguel A R CastanhoFundação GIMM - Gulbenkian Institute for Molecular Medicine Avenida Professor Egas Moniz Lisboa 1649-028 Portugal.ORCID https://orcid.org/0000-0001-7891-7562
Filipa MendesCentro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, CTN, LRS Estrada Nacional 10 2695-066 Bobadela Portugal jgalamba@ctn.tecnico.ulisboa.pt fmendes@ctn.tecnico.ulisboa.pt.ORCID https://orcid.org/0000-0003-0646-1687
Susanne KossatzDepartment of Nuclear Medicine, TUM University Hospital, Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, Technical University of Munich 81675 Munich Germany s.kossatz@tum.de.ORCID https://orcid.org/0000-0002-1908-1782
João D G CorreiaCentro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, CTN, LRS Estrada Nacional 10 2695-066 Bobadela Portugal jgalamba@ctn.tecnico.ulisboa.pt fmendes@ctn.tecnico.ulisboa.pt.ORCID https://orcid.org/0000-0002-7847-4906
Angela CasiniChair of Medicinal and Bioinorganic Chemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich Lichtenbergstrasse 4 85748 Garching bei München Germany angela.casini@tum.de.ORCID https://orcid.org/0000-0003-1599-9542
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Glioblastoma (GBM) is the most aggressive form of malignant brain cancer. Here, we synthesized two chimeric peptide-based radiopharmaceuticals (Comb-1 and Comb-2) targeted to the membrane-bound form of heat shock protein 70 (mHsp70), which is overexpressed in GBM tissues, for future theranostic applications. The design concept features a DOTA chelator for coordination to different radiometals tethered directly or
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Chimeric peptide-based radiopharmaceuticals for glioblastoma imaging and therapy by targeting mHsp70 and enhancing BBB penetration. · full record | OpenQuestion